BIOGNOSYS
Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announces today that it is supporting Cancer Scout as Proteomics provider.
Cancer Scout is a large-scale joint research project led by University Medical Center Göttingen and Siemens Healthineers . The project received funding of EUR 10 million by the German Federal Ministry of Education and Research (BMBF) 1 .
The objective of Cancer Scout is to provide a new Artificial Intelligence tool for precision medicine in the fight against cancer . The research project will analyze and combine genomics, proteomics, and pathology data through Artificial Intelligence to generate a "digital biopsy" of molecular changes in tumors. Identifying these molecular changes can support early and accurate cancer diagnosis and predict personalized therapies for a patient’s tumor.
Oliver Rinner, PhD, CEO and founder of Biognosys states: “We are excited to be part of this visionary multi-omics research project and contribute to the development of more personalized clinical diagnostics and therapies for cancer with our proteomics solutions.”
Biognosys was selected as the provider for the Proteomics data analysis in Cancer Scout, based on its unique technologies and workflows for large-scale proteomics, comprehensive quality standards for clinical research, and extensive expertise in precision oncology.
Biognosys’ discovery proteomics platform utilizes proprietary, patented Hyper Reaction Monitoring (HRM™) mass spectrometry technology to quantify complete proteomes with unmatched precision, depth, and reproducibility. This solution can be applied with high throughput in large-scale studies involving thousands of samples from a broad range of clinical sample types.
Professor Philipp Ströbel, Director of Pathology at the University Hospital Göttingen, comments: “ Combining digital pathology with proteomics and other omics data is essential to identify the full spectrum of molecular changes in tumors and enable truly personalized cancer care.”
Christian Wolfrum, Head of New Business Development and Planning at Siemens Healthineers, adds: “We are excited to work with Biognosys to generate novel scientific insights in Cancer Scout and translate these into personalized cancer care solutions for clinical practice.”
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com .
About University Hospital Göttingen
The University Medical Center Göttingen (UMG) is one of the leading university medical facilities in Germany. For more information, please visit https://www.umg.eu/en/ .
About Siemens Healthineers
To learn more about Siemens Healthineers, please visit siemens-healthineers.com .
1 Funding reference number FKZ 13GW0451A+B
View source version on businesswire.com: https://www.businesswire.com/news/home/20211011005036/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Valorem Reply recognized as Winner of 2025 Microsoft Inclusion Changemaker Partner of the Year12.11.2025 21:30:00 CET | Press release
Valorem Reply, the Reply Group company specializing in Microsoft technologies and AI-driven, cloud-native solutions, announced today it has won the 2025 Microsoft Inclusion Changemaker Partner of the Year Award. The company was honored among a global field of top Microsoft partners for demonstrating excellence in innovation and implementation of customer solutions based on Microsoft technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112917859/en/ The Inclusion Changemaker Partner of the Year Award celebrates partners that lead with inclusive design, accessibility, and innovation to help customers and communities achieve more. “We’re proud of Valorem Reply for earning this recognition,” said Filippo Rizzante, CTO at Reply. “Their work exemplifies our shared commitment to inclusion and to using technology as a catalyst for opportunity and meaningful change. This award reflects the dedication and creativity of the Va
TOURISE 2025 Debuts Agentic Tourism Initiative, Pioneering the Protocol for Intelligent Travel12.11.2025 21:25:00 CET | Press release
The Agentic Tourism Initiative was unveiled today at the inaugural TOURISE Summit, introducing the world’s first Agentic Protocol for Tourism, a universal digital framework set to transform every stage of the traveler’s journey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112353634/en/ His Excellency Ahmed Al Khateeb, Saudi Arabia's Minister of Tourism and Chairman of TOURISE, launches the Agentic Tourism Initiative on the second day of TOURISE. Launched in partnership with TOURISE and Globant, the Initiative builds on the momentum of the acclaimed whitepaper Tourism’s AI Takeover: Reinventing Travel through Agentic Tourism to create a landmark application of AI. It directly answers the whitepaper’s call to create an Open Protocol for Tourism AI, defining how AI agents interact from inspiration to return. The result: intelligent, seamless, and sustainable travel experiences across the global tourism ecosystem. The Init
NetApp Recognized as Winner of 2025 Microsoft Americas Partner of the Year for SDC Canada Category12.11.2025 21:00:00 CET | Press release
NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced it has won the 2025 Americas Partner of the Year Software Development Company (SDC) Canada Award. The company received recognition among a group of top Microsoft partners for demonstrating innovation and successfully delivering customer solutions using Microsoft technologies. “We believe that being honored by Microsoft as the 2025 Americas Partner of the Year for the SDC Canada category is a powerful validation of our unmatched innovation and impact for customers across industries,” said Pravjit Tiwana, Senior Vice President and General Manager, Cloud Storage and Services at NetApp. “We are the only storage company natively embedded in Microsoft Azure as a first-party service—a distinction that underscores the depth of our collaboration. Together we’re not only helping customers modernize their workloads at scale—we're architecting the foundation for the AI era.” The Microsoft Americas Partner of the Y
TOURISE Awards 2025: Tokyo, New York, Ancash and Paris Take Top Honors at Inaugural TOURISE Awards12.11.2025 19:31:00 CET | Press release
The very first winners of the TOURISE Awards have been announced, recognizing the destinations redefining exploration, hospitality, and cultural connection for the modern traveler, setting new benchmarks for innovation and excellence to deliver truly unforgettable visitor experiences. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112648089/en/ His Excellency Ahmed Al-Khateeb, Minister of Tourism and TOURISE Chairman, celebrates with the winners of the TOURISE Awards Taking place as part of the inaugural TOURISE Summit, held under the patronage of His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister, Tokyo, Japan, emerged as the big winner, clinching the coveted title of Best Overall Destination. In addition, Tokyo was also recognized as both the Best Food & Culinary and Best Entertainment destination, affirming its status as a global capital of innovation, energy, and unfor
Brenus Pharma Expands Its Global Scientific Advisory Board With Us Immuno-Oncology Expert Prof. Olivera J. Finn12.11.2025 19:00:00 CET | Press release
Brenus Pharma, a clinical-stage biotechnology company developing first-in-class in vivo immunotherapies for solid tumors, announced the appointment of Olivera J. Finn, Distinguished Professor at the University of Pittsburgh School of Medicine, to its Scientific Advisory Board (SAB). This strategic addition strengthens Brenus’ international SAB as the company advances its proprietary Stimulated Ghost Cell (SGC) platform and lead candidate STC-1010 toward its next clinical milestones. Globally recognized for her groundbreaking contributions to cancer immunology, Prof. Finn has led major discoveries in tumor antigens. She identified the MUC1 tumor antigen, a cornerstone in cancer research, and discovered cyclin B1 as a promising target for anti-cancer immunotherapy. Over her career, she has authored more than 220 peer-reviewed publications and co-led extensive clinical trials across pancreatic, colon, breast, prostate, and lung cancers. She also served as President of the American Associa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom